Recent Updates
Recently added Catalysts

Deupirfenidone

Phase 3

Idiopathic Pulmonary Fibrosis (IPF) | Small molecule | Respiratory |PureTech Health plc|Last Updated: Mar 5, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment1,100
FDA Designations
No designations recorded
Clinical trial landscape

Deupirfenidone · 2 trials · 2 indications

Phase 3 1Phase 1 1
NCT07284602Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)
NOT YET_RECRUITING1,100 Analytics
PHASE3NOT YET_RECRUITING
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
NCT072846021,100
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
DeupirfenidoneDRUGsize AA Swedish orange capsule
Pirfenidone (PFD)DRUGsize AA Swedish orange capsule
PlaceboDRUGSwedish orange capsule
Unlock Study Design Details
Competitive Landscape -Idiopathic Pulmonary Fibrosis 20 trials (matched to "Idiopathic Pulmonary Fibrosis (IPF)")
CompanyTickerTrialsLead PhaseDrugs
Bristol-Myers Squibb CompanyBMY2PHASE3BMS-986278
United Therapeutics CorporationUTHR2PHASE3Treprostinil
PureTech Health PLC Sponsored ADRPRTC2PHASE3Deupirfenidone, Pirfenidone
AbbVie, Inc.ABBV2PHASE2ABBV-142
Syndax Pharmaceuticals IncSNDX1PHASE2Axatilimab
Contineum Therapeutics, Inc. Class ACTNM1PHASE2PIPE-791 Dose A, PIPE-791 Dose B
Rein Therapeutics, IncRNTX1PHASE2LTI-03
Sunshine Biopharma IncorporatedSBFM2PHASE3HEC585, Pirfenidone
Cumberland Pharmaceuticals Inc.CPIX1PHASE2Ifetroban
Avalyn Pharma IncAVLN3PHASE2AP01
Trevi Therapeutics, Inc.TRVI1PHASE1NAL
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT07284602studyFirstPostDate: changed